 Home > Active Ingredient News > Antitumor Therapy > BMC Cancer: The team of Academician Xu Binghe analyzed the clinicopathological characteristics and survival prognosis of patients with metastatic breast cancer with simultaneous lung metastasis in the Han population in China

BMC Cancer: The team of Academician Xu Binghe analyzed the clinicopathological characteristics and survival prognosis of patients with metastatic breast cancer with simultaneous lung metastasis in the Han population in China

 Last Update: 2022-01-08
 Source: Internet
 Author: User

Tags

breast neoplasm

triple batteries

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Lung metastasis is breast cancer the second most common sites of distant metastases, accounting for 15-25% of metastatic breast cancer (MBC) patients clinically
.

Systemic treatments including chemotherapy, targeted therapy and endocrine therapy are recommended for patients with breast cancer lung metastasis (BCLM), and lung metastasis resection is also recommended for appropriately selected cases

Lung metastasis is breast cancer the second most common sites of distant metastases, accounting for 15-25% of metastatic breast cancer (MBC) patients clinically

Research Screening 2000 Nian 4 months to 2019 Nian 9 Monthly first diagnosis of 3155 Li MBC patients with clinical data, and ultimately into the MBC patients with 2263 cases, of which 809 patients were first diagnosed MBC lung metastasis occurs
.

Multivariate logistic regression analysis was used to determine the risk factors of BCLM , and univariate and multivariate Cox regression analysis were used to evaluate the prognostic factors of BCLM patients

Among the 2263 MBC patients, there were 809 cases (35.
7%) of patients with concurrent lung metastasis (BCLM)

Among 2263 cases of MBC, HR+/HER2-, HR- /HER2+, HR+/HER2+ and triple negative subtypes accounted for 52.

Incidence of lung metastasis of different breast cancer subtypes

The incidence of lung metastasis of different breast cancer subtypes The incidence of lung metastasis of different breast cancer subtypes The incidence of lung metastasis of different breast cancer subtypes

Age ≥50 years (vs <50 years, OR = 1.
29, 95% CI 1.
54 = 1.
08, p = 0.
005), ECOG=2 (vs ECOG 0, OR = 1.
67, 95% CI 2.
67 = 1.
04, p = 0.
033), M1 (vs M0, OR = 1.
42, 95% CI 1.
92 = 1.
05, p = 0.
022), HR-/HER2 + subtype (vs HR+ / HER2 -, OR = 1.
40, 95% CI 1.
85 = 1.
06, p = 0.
020) , Triple negative subtype (vs HR+ / HER2 -, OR= 1.
63, 95% CI 2.
09 = 1.
28, p<0.
001) and DFS>2 years (vs.
DFS<2 years, OR = 1.
74, 95% CI = 1.
42 2.
14 , p<0.
001) was significantly related to the increase in the incidence of lung metastases at the time of diagnosis
.

Invasive lobular carcinoma (ILC) (vs invasive ductal carcinoma (IDC), OR = 0.

Age ≥50 years (vs <50 years, OR = 1.

The median follow-up time of the entire MBC cohort was 61.

The prognostic difference of MBC with or without lung metastasis

The prognostic difference of MBC with or without lung metastasis The prognostic difference of MBC with or without lung metastasis

Patients with HR+/HER2-subtype BCLM had the longest survival time (49.
0 months), and triple-negative (26.
8 months, p<0.
001) the shortest
.

The median OS of HR- /HER2+ (vs.

Patients with HR+/HER2-subtype BCLM had the longest survival time (49.

The prognostic differences of different molecular subtypes in BCLM patients

The prognostic differences of different molecular subtypes in BCLM patients The prognostic differences of different molecular subtypes in BCLM patients

Triple negative subtype (vs.
HR+/HER2-, HR = 1.
76, 95% CI = 1.
36 2.
29, p<0.
001), liver metastasis (vs.
no liver metastasis, HR = 2.
19, 95% CI = 1.
70 2.
82, p< 0.
001), 2 metastasis sites (vs.
1 metastasis site, HR = 1.
76, 95% CI = 1.
34 2.
31, p<0.
001), ≥3 metastasis sites (vs.
1 metastasis site, HR = 1.
74, 95% CI = 1.
24 2.
44, p = 0.
001) was significantly related to the poor survival of patients with BCLM
.

DFS>2 years (vs.
DFS≤2 years, HR = 0.
66, 95% CI = 0.
53 0.
83, p<0.
001) is associated with a good prognosis in patients with BCLM
.

Multivariate analysis of OS in BCLM patients

Multivariate analysis of OS in BCLM patients Multivariate analysis of OS in BCLM patients

In summary, the study provides important information on the clinicopathological characteristics and survival results of patients with lung metastases (BCLM) in the
Han Chinese population when MBC was first diagnosed .
In summary, the study provides the first diagnosis of Chinese Han population .
The study provides the first diagnosis of Chinese Han population.
The study provides important information on the clinicopathological characteristics and survival results of patients with lung metastasis (BCLM) when
the Chinese Han population was first diagnosed with MBC.
.
MBC is accompanied by important information about the clinicopathological characteristics and survival results of patients with lung metastasis (BCLM)
.

Original source:

Lin S, Mo H, Li Y, Guan X, Chen Y, Wang Z, Xu B.
Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population.
BMC Cancer.
2021 Dec 14;21 (1):1330.
doi: 10.
1186/s12885-021-09038-2.
PMID: 34906122; PMCID: PMC8670055.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.